Hepatitis D
INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS, a defective RNA virus that can only infect HEPATITIS B patients. For its viral coating, hepatitis delta virus requires the HEPATITIS B SURFACE ANTIGENS produced by these patients. Hepatitis D can occur either concomitantly with (coinfection) or subsequent to (superinfection) hepatitis B infection. Similar to hepatitis B, it is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
Subtype terms (1)
More specific conditions that are subtypes of Hepatitis D in the MeSH hierarchy.
- Hepatitis D, Chronic
19 drugs (10 approved, 9 experimental)
Drugs by status
Phase 2 trials (13)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (5)
Organization Involved with Phase 2 Indications (13)
- Gilead Sciences
- Arrowhead Pharmaceuticals
- Hannover Clinical Trial Center GmbH
- Replicor Inc.
- German Liver Foundation
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Gottfried Wilhelm Leibniz Universität Hannover
- Aga Khan University
- University of Ankara
- Moscow Regional Resarch adn Clinical Institute
- Janssen Pharmaceutica NV
- Data Matrix, LTD
- Ziauddin University
Organization Involved with Phase 1 Indications (1)